Revolution Medicines (RVMD) EBT (2019 - 2026)

Revolution Medicines' EBT history runs 8 years deep, the most recent figure standing at -$453.8 million for Q1 2026.

• In Q1 2026, EBT fell 112.64% year-over-year to -$453.8 million; the TTM figure through Mar 2026 stood at -$240.4 million (up 65.57% YoY), while the FY2024 annual figure was -$600.8 million, down 36.59% from the prior year.
• EBT for Q1 2026 stood at -$453.8 million, down from $766.4 million in the prior quarter.
• The five-year high for EBT was $766.4 million in Q4 2025, with the low at -$453.8 million in Q1 2026.
• The 5-year median for EBT is -$116.0 million (2024), against an average of -$102.6 million.
• The sharpest annual moves came in 2023 and 2025: EBT slumped 184.64% in 2023, then soared 492.38% in 2025.
• Revolution Medicines' EBT stood at -$56.6 million in 2022, then plunged by 184.64% to -$161.2 million in 2023, then decreased by 21.17% to -$195.3 million in 2024, then jumped by 492.38% to $766.4 million in 2025, then slumped by 159.21% to -$453.8 million in 2026.
• Business Quant data shows RVMD's EBT at -$453.8 million in Q1 2026, $766.4 million in Q4 2025, and -$305.2 million in Q3 2025.